Trial Profile

Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NGR-TNF (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
Focus Therapeutic Use
Acronyms Ingrid

02 Aug 2022 Status changed from recruiting to completed.
04 Dec 2018 Results (n=22) reporting activity, safety and Blood Brain Barrier permeabilization, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
04 Jun 2018 According to MolMed media release, data from this trial will be presented at ASCO.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com